You can narrow down the results using the filters
-
Bowel cleansing for colonoscopy a new approach: a randomised study of bisacodyl tablets and diet versus standard bowel preparation.
Expand descriptionThe aim of this project is to study a new way of cleaning the bowel prior to colonoscopy. Current methods of cleaning the bowel are very effective but have some limitations. Bowel preparation currently involves drinking a large volume of salty tasting fluid which many patients do not like. An alternative method involves drinking a smaller volume of solution that can cause complications associated with dehydration and decreased salt levels within the body. In this study we will evaluate a new way of cleaning the bowel involving the use of a more gentle tablet laxative and diet restrictions in the three days before your colonoscopy. We are also interested in how you as the patient feel about this method of cleaning the bowel and we will ask you to fill in a questionnaire prior to your colonoscopy. The laxative we are using in this trial (Dulcolax) is freely available and works by stimulating the colon to pass bowel motions. It is a safe drug that is proven to be effective in helping empty the bowel. Dulcolax (bisacodyl) is approved by the Therapeutic Goods Administration of Australia to treat constipation and evacuation of the bowel. This study will be conducted at The Western Hospital Footscray. 200 people will be asked to participate in this trial.
-
Radiotherapy following radical prostatectomy - Adjuvant Versus Early Salvage
Expand descriptionThis study aims to compare two different radiotherapy regimes following radical prostatectomy in men with prostate cancer. Who is it for? You may be eligible to join this study if you a male aged 18 years or above who has undergone a radical prostatectomy (RP) for prostate cancer, and are able to start radiotherapy within 4 months of RP. Study details Participants in this study will be randomly (by chance) allocated to one of two groups. Participants in one group will receive the current standard of care treatment, which consists of adjuvant radiation therapy (ART) commenced within 4 months of radical prostatectomy. Participants in the other group will instead undergo active surveillance, where salvage radiotherapy (SRT) will not commence until Prostate Specific Antigen (PSA) reaches a level greater than 0.2ng/ml. Both radiotherapy regimes will be delivered once per day over approximately 6.5 weeks. Quality of life self-assessment questionnaires, Hospital Anxiety and Depression Score and toxicity will be assessed at baseline, the end of radiotherapy and annually for 5 years. Patients will be seen by their doctor 6 monthly for the first 5 years, then annually for the next 5 years. A blood test measuring PSA is done 3 monthly for the first 5 years for patients randomised to early SRT, than 6 monthly from years 5-10.
-
The neural basis and treatment of reading disability in children with neurofibromatosis type 1
Expand descriptionThe study has two parts - Part A and Part B. Participants can choose to participate in Part A alone or both parts of the study. The aim of Part A is to see if a computer-based training program can improve the reading of children with neurofibromatosis type 1 (NF1) and reading difficulties. Many children with NF1 experience difficulty reading, particularly when sounding out unfamiliar words (phonological dyslexia). It is hypothesised that by teaching these children letter-sound relationships (phonics) their reading and reading related skills (e.g. spelling) will improve. The aim of Part B is to identify parts of brain tissue and structure that may be related to children's reading abilities.
-
A randomised controlled trial investigating the efficacy of Eleutherococcus senticisus (Araliacae: Siberian ginseng) on the amelioration of the symptoms of overtraining syndrome in Ironman triathletes
Expand descriptionThe hypothesis is that overtraining syndrome due to hypothalamic dysfunction and that Eleutherococcus will assist in preventing overtrainign syndrome. Evidence for hypothalamic dysfunction is made by changes in waking core body temperature, and also by measuring changes in corticotrophic releasong hormine (CRH) which is released by the hypothalamus in times of stress. This hormone CRH in turn stimulates the pituitary gland to release adrenocorticotrophic hormone (ACTH) which stimulates the adrenal cortex to release cortisol. Cortisol is a stress hormone. All three of these hormones are measured at 0, 6 and 12 weeks. The study will determine if there is any difference in these hormones between the control cohort and the active ingerdient cohort
-
A trial to evaluate the effects of different monosaccharide preloads on incretin hormone secretion, gastric emptying and post-meal blood glucose in healthy subjects and patients with type 2 diabetes mellitus.
Expand descriptionThe study will evaluate the effects of different sugars on the release of the incretin hormone GLP-1 from the small intestine, and how this affects the gastric emptying of, and glycaemic response to, a subsequent meal, in both healthy subjects and patients with type 2 diabetes.
-
Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial
Expand descriptionDoes routine administration of fluoxetine (20mg od) in the 6 months after acute stroke improve patients’ functional outcome?
-
Does osteoarthritis of the hip make failure of internal fixation more likely? A comparison of all hip fractures, comparing the presence of osteoarthritis to rates of failure.
Expand descriptionAim: The aim of this study is to determine whether a diagnosis of osteoarthritis (OA) in the hip, makes failure of internal fixation in hip fractures more likely; in the patient population group undergoing internal fixation for proximal femoral fractures at any Western Australian tertiary hospital between 2002-2004. Importance: Hip fractures are very common in Australia and are associated with high mortality and morbidity. The number of hip fractures in Australian women is projected to increase from 11 300 per year in 1996 to 44 700 in 2051; In men, the number is projected to rise from 4 000 to 15 300. The cost of this clinical problem is estimated at between 0.9-1.4% of the total government healthcare expenditure. Most will be managed with surgery, through internal fixation. This process can fail (failure of internal fixation). Many of the patient factors behind failure of fixation are unknown. Through clinical observation it is assumed that OA does increase the likelihood of fixation failure, however no published research exists to support this assumption. The reasons behind why OA may have this effect relates to alterations in bone homeostasis. Given that OA is highly prevalent in our society it is important to determine if a link exists between hip OA and failure of fixation. If a link is established, this information would assist clinicians in the choice of an appropriate fixation technique and reduce the likelihood of failure and therefore reoperation. This information would contribute to an improved efficiency of health care provision in this patient group. In addition, it would serve to use the limited health dollar more efficaciously. Methods: This is a multi-centred study in which data will be collected retrospectively, investigating an estimated 700-800 patients records, across the three tertiary hospitals in Western Australia, where internal fixation was performed after hip fracture. This sample size will allow study estimates to be representative of the population estimate. The presence of OA at time of fracture will be identified. Failure of internal fixation will be identified over a four year follow-up period. The collected data will be analysed using a Proportional Hazard Regression model (Cox Regression model) to measure rates of failure of fixation between two patient groups: the patient group with no hip OA and the patient group with hip OA. Benefits: The median cost for hospital treated proximal femoral fractures is approximately $15,984 per fracture. Reducing the number of fixation failures would therefore result in measurable reductions to health care budget expenditure, in combination with the reduction in mortality and morbidity associated with reoperation.
-
Nutrition supplementation and immunity in athletes
Expand descriptionThis study will investigate 28 days of butyrylated resistant starch supplementation on faecal short chain fatty acids, faecal microbiology and immunity in well trained athletes. Well trained athletes undertaking prolonged endurance exercise suffer gastrointestinal dysfunction and suppression of immunity from heavy exercise training. This supplement is being investigated to examine whether it may reverse these issues.
-
Securing Arterial and Venous devices Effectively in hospitals (The SAVE trial)
Expand descriptionGoing to hospital usually means having an intravascular device (“IV drip”) in your vein or artery. Almost half of all IV drips fall out or fail because they are not well secured to the skin. This means patients miss out on treatment and have extra painful needlesticks to insert new devices. Serious infections can also occur. This study will find the best dressings to use on IV drips. Patients will have their drips glued in with medical superglue, or have one of two new dressings, compared with current usual care.
-
Early Years Education Research Project
Expand descriptionThis project will undertake a randomised evaluation of an intervention for socially disadvantaged children, the Early Years Education Program (EYEP). EYEP is a new program being offered by the Children’s Protection Society (CPS). The project will examine effects of program participation on outcomes such as children’s cognitive, speech, language and emotional development, their health and school readiness, and on the parent-child relationship, and parents’ health and community participation. The EYEP will provide enrolled children with at least 25 hours per week of enriched centre based child care and education for three years (or until school age). Children must be less than 3 years of age at the time of their initial enrolment into EYEP. Key features of this program are high staff:child ratios, qualified staff, therapeutic interventions with the child and family, integration with family support services, and a focus on building alliances with parents to sustain their child’s participation in child care. Referrals of children eligible for enrolment in EYEP will be from clients of child welfare services including family casework services accessed through Child FIRST (Family Information Referral Support Team) and Child Protection. Children eligible for participation will be aged less than 3 years at referral, and assessed as having experienced at least two identified risk factors such as family violence, parental mental health problems, or parental drug and alcohol use. The referred group of children who are eligible for participation in EYEP will be randomly assigned between a treatment group who will be enrolled in the EYEP and a control group who will receive ‘usual care’. The trial will involve data collection standardized questionnaires completed by parents and child care staff, interviews with parents, standardized assessments (for example, cognitive functioning), and observation of child behaviour in the early child care centre classroom and with parents. This will occur over a three year period – baseline and then at yearly intervals. The importance of the project derives from its potential contribution to knowledge of how enhanced childcare might contribute to improved social and educational outcomes for children from highly disadvantaged backgrounds. Currently fewer than 16% of Child FIRST clients in the north eastern region attend child care or kindergarten despite early child care and education services being a potential resource for children at risk. To our knowledge this will be the first randomised trial of an early childhood intervention in Australia.